Blonanserin

CAS No. 132810-10-7

Blonanserin ( AD5423; Lonasen )

Catalog No. M11308 CAS No. 132810-10-7

Blonanserin is a novel atypical antipsychotic agent with potent dopamine D2 and serotonin 5-HT2 receptors antagonist properties.

Purity : >98%(HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 28 In Stock
10MG 43 In Stock
25MG 77 In Stock
50MG 113 In Stock
100MG 158 In Stock
200MG 284 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Blonanserin
  • Note
    Research use only, not for human use.
  • Brief Description
    Blonanserin is a novel atypical antipsychotic agent with potent dopamine D2 and serotonin 5-HT2 receptors antagonist properties.
  • Description
    Blonanserin is a novel atypical antipsychotic agent with potent dopamine D2 and serotonin 5-HT2 receptors antagonist properties.
  • Synonyms
    AD5423; Lonasen
  • Pathway
    Endocrinology/Hormones
  • Target
    5-HT Receptor
  • Recptor
    5-HT2; D2
  • Research Area
    Neurological Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    132810-10-7
  • Formula Weight
    367.50
  • Molecular Formula
    C23H30FN3
  • Purity
    >98%(HPLC)
  • Solubility
    Ethanol: <1 mg/mL (<1 mM); Water: <1 mg/mL (<1 mM); DMSO: <1 mg/mL (<1 mM)
  • SMILES
    CCN1CCN(CC1)C1=NC2=C(CCCCCC2)C(=C1)C1=CC=C(F)C=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Kawabe K, et al. Clin Neuropharmacol. 2013, Nov-Dec; 36(6):239-4
molnova catalog
related products
  • SUVN-502 mesylate

    SUVN-502 (SUVN502)is a potent, selective, brain penetrant and orally active 5-HT6 receptor antagonist with Ki of 2.04 nM.

  • Fluvoxamine maleate

    Fluvoxamine maleate is a selective serotonin (5-HT) reuptake inhibitor (SSRI).

  • Ondansetron hydrochl...

    Ondansetron is a serotonin 5-HT receptor antagonist used mainly as anantiemetic (to treat nausea and vomiting), often following chemotherapy.